Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNXP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTonix publishes Phase 1 results showing TNX-1500 blocked immune responses at all doses
Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
high
TNX-1500 successfully blocked primary immune responses at all three tested doses (3, 10, and 30 mg/kg) in 26 healthy volunteers, with higher doses also blocking secondary responses and the lowest dose reducing them by 70%.
Item 8.01 verify on EDGAR → -
high
Peer-reviewed publication in Journal of Clinical Immunology validates first-in-human Phase 1 trial data for TNX-1500, an antibody being developed to prevent organ transplant rejection and treat autoimmune diseases.
Item 8.01 verify on EDGAR → -
medium
The randomized, double-blind, placebo-controlled study used single-ascending doses and monitored participants for 120 days, evaluating safety, tolerability, pharmacokinetics, and immune response suppression.
Item 8.01 verify on EDGAR →
Summary
Tonix Pharmaceuticals announced publication of Phase 1 clinical trial results for TNX-1500, a monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. The peer-reviewed study in the Journal of Clinical Immunology showed the drug successfully blocked immune responses at all tested dose levels in 26 healthy volunteers, with dose-dependent effects on secondary immune responses.
Retail investors should view this as a positive early-stage milestone. Peer-reviewed publication adds credibility to the data and validates the drug's mechanism of action in humans. The dose-dependent efficacy suggests a clear path forward for dose selection in future trials.
However, this is still Phase 1 data in healthy volunteers—the drug's performance in actual transplant patients or autoimmune disease patients remains to be proven. Watch for announcements about Phase 2 trial initiation, which would test TNX-1500 in patient populations. Also monitor for any partnership discussions, as transplant and autoimmune therapies often attract interest from larger pharmaceutical companies seeking to expand their immunology portfolios.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 27, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the publication of a paper, “First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults,” in the peer-reviewed Journal of Clinical Immunology (the “Manuscript”).
The company disclosed publication of Phase 1 clinical trial results for TNX-1500, an Fc-modified anti-CD154 monoclonal antibody. The study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses in healthy adults. This represents a milestone in the drug's development pathway, providing peer-reviewed validation of early-stage clinical data.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 27, 2026, the Company announced the publication of the Manuscript, which reports findings from a single-center, first-in-human, Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose escalation study in 26 healthy adult volunteers of the Company’s TNX-1500 product candidate, a monoclonal antibody in development for the prevention of organ transplant rejection and the treatment of autoimmune diseases.
Tonix disclosed results from its first-in-human Phase 1 study of TNX-1500, a monoclonal antibody being developed to prevent organ transplant rejection and treat autoimmune diseases. The study enrolled 26 healthy volunteers in a randomized, double-blind, placebo-controlled design testing three dose levels (3, 10, and 30 mg/kg).
Added in current filing · verify on EDGAR →
TNX-1500 blocked the primary TDAR to KLH at all doses, blocked the secondary response at the 10 and 30 mg/kg doses, and reduced peak secondary response to KLH by approximately 70% relative to placebo at the 3 mg/kg dose.
The trial demonstrated that TNX-1500 successfully blocked primary immune responses at all three dose levels tested. At the two higher doses (10 and 30 mg/kg), it also blocked secondary immune responses, while the lowest dose (3 mg/kg) reduced secondary responses by approximately 70% compared to placebo. These results suggest dose-dependent efficacy in suppressing T cell-dependent antibody responses.
Added in current filing · verify on EDGAR →
Participants were enrolled across three ascending dose cohorts (3, 10, and 30 mg/kg) or placebo and received a single intravenous infusion of TNX-1500 or placebo, followed by intramuscular injections of keyhole limpet hemocyanin (“KLH”) on days 2 and 29 to assess the primary and secondary T cell-dependent antibody responses (“TDAR”), and monitored over a 120-day follow-up period.
The study used a single-ascending dose design with participants receiving one intravenous infusion of TNX-1500 or placebo, then being challenged with KLH injections on days 2 and 29 to test immune response suppression. Participants were monitored for 120 days, providing safety and efficacy data across the follow-up period.
Event · Item 9.01 — Financial Statements and Exhibits
Tonix disclosed Phase 1 clinical trial results for TNX-1500, an anti-CD154 monoclonal antibody, in healthy adults.
Added in current filing · verify on EDGAR →
First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults
Tonix disclosed results from a first-in-human Phase 1 clinical trial of TNX-1500, an Fc-modified anti-CD154 monoclonal antibody. The study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses in healthy adults using a randomized, double-blind, placebo-controlled design. This represents a key early-stage clinical milestone for the drug candidate.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify